Hormone Therapy for Prostate Cancer: Exploring Current Controversies Francesco Montorsi, Richard Berges, Jacques Irani, Claude C. Schulman  European Urology Supplements  Volume 8, Issue 9, Pages 725-732 (September 2009) DOI: 10.1016/j.eursup.2009.05.001 Copyright © 2009 European Association of Urology Terms and Conditions

Fig. 1 The effect of 3 mo versus 8 mo of neoadjuvant androgen deprivation therapy (ADT) prior to conventional-dose radiotherapy (RT) on disease-free survival for low-risk, intermediate-risk, or high-risk localised prostate cancer (PCa) in a Canadian phase 3 trial [20]. NS=not significant. European Urology Supplements 2009 8, 725-732DOI: (10.1016/j.eursup.2009.05.001) Copyright © 2009 European Association of Urology Terms and Conditions

Fig. 2 Ten-year follow-up results of the Radiation Therapy Oncology Group (RTOG) 92-02 trial evaluating long-term (2 yr) adjuvant hormone therapy (LTAD) over short-term (4 mo) adjuvant hormone therapy (STAD) with radiotherapy (RT) in locally advanced prostate cancer [22]. NS=not significant. European Urology Supplements 2009 8, 725-732DOI: (10.1016/j.eursup.2009.05.001) Copyright © 2009 European Association of Urology Terms and Conditions

Fig. 3 Overall survival data of the South European Uroncological Group (SEUG) trial comparing intermittent (Int; n=314) with continuous (Cont; n=312) maximal androgen blockade in patients with T3-T4 M0-1 prostate cancer who did not receive previous treatment [32]. Reprinted with permission from Elsevier. European Urology Supplements 2009 8, 725-732DOI: (10.1016/j.eursup.2009.05.001) Copyright © 2009 European Association of Urology Terms and Conditions

Fig. 4 Preferred frequency of injections for patients aged ≤70 yr (n=89) or >70 yr (n=111) [40]. European Urology Supplements 2009 8, 725-732DOI: (10.1016/j.eursup.2009.05.001) Copyright © 2009 European Association of Urology Terms and Conditions